NCT00856687 is a Phase 1 clinical trial of PF-03893787 in Asthma, sponsored by Pfizer.

Who is sponsoring NCT00856687?

NCT00856687 is sponsored by Pfizer.

What drugs are being tested in NCT00856687?

Interventions in NCT00856687: PF-03893787, Placebo, Montelukast.

Is NCT00856687 still recruiting?

NCT00856687 is currently completed. Last updated 21 January 2010.

Last reviewed 2010-01-21 · How we verify

NCT00856687

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Randomized, Double-Blind (3rd Party Open), Double-Dummy, Placebo- And Active Controlled, 3-Way Crossover Study To Determine The Effects Of Oral PF-03893787 On Allergen-Induced Airway Responses In Mild Asthmatic Subjects.

Completed Phase 1 Last updated 21 January 2010

What this trial tests

Phase 1 trial testing PF-03893787 in Asthma in 12 participants. Completed in 1 December 2009.

Timeline

1 April 2009

Primary endpoint
1 December 2009

1 December 2009

Quick facts

Lead sponsor	Pfizer
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	double
Primary purpose	treatment
Enrollment	12
Start date	1 April 2009
Primary completion	1 December 2009
Estimated completion	1 December 2009
Sites	1 location across United Kingdom

Drugs / interventions tested

PF-03893787 — full drug profile →
Placebo
Montelukast (montelukast) — full drug profile →

Conditions studied

Asthma — all drugs for Asthma →

Sponsor

Pfizer — full company profile →

Who can join

Adults 18 to 60, any sex, with Asthma. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Spirometry pre- and post- bronchial allergen challenge
Time frame: 2 months

Sponsor's own description

PF-03893787, a novel anti-inflammatory agent should attenuate the effect of a bronchial allergen challenge on lung function and hence provide proof of mechanism for this agent.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

The histamine H4 receptor: from orphan to the clinic.
Thurmond RL. · · 2015 · cited 85× · PMID 25873897 · DOI 10.3389/fphar.2015.00065
Histamine H₄ receptors in the gastrointestinal tract.
Deiteren A, De Man JG, Pelckmans PA, De Winter BY. · · 2015 · cited 45× · PMID 25363289 · DOI 10.1111/bph.12989
New antihistamines - perspectives in the treatment of some allergic and inflammatory disorders.
Tatarkiewicz J, Rzodkiewicz P, Żochowska M, Staniszewska A, et al · · 2019 · cited 19× · PMID 30899308 · DOI 10.5114/aoms.2017.68534

Verify or expand the search:

Other recruiting trials for Asthma

Currently open trials in the same condition.

NCT07525375 — A Phase II Study to Investigate Lung Function With 2 Different Doses of Inhaled Glycopyrronium Taken With BFF Compared t · Phase 2 · recruiting
NCT07536256 — Community Connections Through Native Hawaiian Cultural Values to Strengthen Youth Resilience, Health, and Well-Being · NA · recruiting
NCT07556159 — A Study Evaluating Disease Characteristics and Outcomes in Participants With Asthma in Routine Clinical Practice · recruiting
NCT07282886 — VENTURI (VENTilation Using Respiratory Imaging) · Phase 2 · recruiting
NCT07433569 — A Study to Investigate How Budesonide and Formoterol Move Through the Body (Pharmacokinetics) When Delivered With Differ · Phase 1 · recruiting

Other Pfizer trials

Trials by the same sponsor.

NCT04982848 — Korea Post Marketing Surveillance (PMS) Study of Talzenna® · not yet recruiting
NCT06873191 — A Study to Learn More About Tukysa Once it is Out in the Korean Market · not yet recruiting
NCT07497854 — A Study to Learn About the Study Medicine NURTEC® ODT 75 mg After it is Released Into the Markets in Korea · not yet recruiting
NCT06507904 — A Study to Learn How Different Preparations of Osivelotor Taste and Enter the Blood With Food or Liquids or With an Anta · Phase 1 · not yet recruiting
NCT06864585 — A Study to Learn About the Study Medicine - Zavicefta in Patients With Sepsis or Loss of Kidney Function in Japan · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00856687 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Pfizer
Last refreshed: 21 January 2010

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00856687.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing